EP3775267A4 - Nouveaux antagonistes doubles de vegf et de l'angiopoïétine 2 - Google Patents

Nouveaux antagonistes doubles de vegf et de l'angiopoïétine 2 Download PDF

Info

Publication number
EP3775267A4
EP3775267A4 EP19784270.1A EP19784270A EP3775267A4 EP 3775267 A4 EP3775267 A4 EP 3775267A4 EP 19784270 A EP19784270 A EP 19784270A EP 3775267 A4 EP3775267 A4 EP 3775267A4
Authority
EP
European Patent Office
Prior art keywords
dual antagonists
novel angiopoietin
vegf dual
vegf
angiopoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19784270.1A
Other languages
German (de)
English (en)
Other versions
EP3775267A2 (fr
Inventor
Yuefeng Lu
Jian-Feng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askgene Pharma Inc
Original Assignee
Askgene Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askgene Pharma Inc filed Critical Askgene Pharma Inc
Publication of EP3775267A2 publication Critical patent/EP3775267A2/fr
Publication of EP3775267A4 publication Critical patent/EP3775267A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
EP19784270.1A 2018-04-10 2019-04-10 Nouveaux antagonistes doubles de vegf et de l'angiopoïétine 2 Pending EP3775267A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655436P 2018-04-10 2018-04-10
PCT/US2019/026838 WO2019200006A2 (fr) 2018-04-10 2019-04-10 Nouveaux antagonistes doubles de vegf et de l'angiopoïétine 2

Publications (2)

Publication Number Publication Date
EP3775267A2 EP3775267A2 (fr) 2021-02-17
EP3775267A4 true EP3775267A4 (fr) 2022-05-18

Family

ID=68164868

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19784270.1A Pending EP3775267A4 (fr) 2018-04-10 2019-04-10 Nouveaux antagonistes doubles de vegf et de l'angiopoïétine 2

Country Status (3)

Country Link
EP (1) EP3775267A4 (fr)
CN (1) CN112262158B (fr)
WO (1) WO2019200006A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197199A1 (fr) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Nouveaux antagonistes doubles d'angiopoïétine 2, vegf
PE20230986A1 (es) 2020-09-04 2023-06-21 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y metodos de uso
WO2022206838A1 (fr) * 2021-03-31 2022-10-06 Hangzhou Jiayin Biotech Ltd. Molécules de fusion ciblant vegf et les angiopoïétines et leurs utilisations
US20240279324A1 (en) * 2021-06-03 2024-08-22 Gensun Biopharma Inc. Multispecific antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073915A1 (fr) * 2014-11-07 2016-05-12 Novartis Ag Formulation de solution de protéines stable contenant une forte concentration d'un anticorps anti-vegf
WO2017197199A1 (fr) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Nouveaux antagonistes doubles d'angiopoïétine 2, vegf

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073915A1 (fr) * 2014-11-07 2016-05-12 Novartis Ag Formulation de solution de protéines stable contenant une forte concentration d'un anticorps anti-vegf
WO2017197199A1 (fr) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Nouveaux antagonistes doubles d'angiopoïétine 2, vegf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHAUWVLIEGHE A. M. E. ET AL: "Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study", PLOS ONE, vol. 11, no. 5, 1 May 2016 (2016-05-01), pages e0153052, XP055909670, DOI: 10.1371/journal.pone.0153052 *

Also Published As

Publication number Publication date
WO2019200006A2 (fr) 2019-10-17
CN112262158A (zh) 2021-01-22
EP3775267A2 (fr) 2021-02-17
CN112262158B (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
EP3454903A4 (fr) Nouveaux antagonistes doubles d'angiopoïétine 2, vegf
EP3754122A4 (fr) Engin de chantier
EP3775267A4 (fr) Nouveaux antagonistes doubles de vegf et de l'angiopoïétine 2
EP3748086A4 (fr) Engin de chantier
EP3849047A4 (fr) Engin de chantier électrique
EP3899740A4 (fr) Sélection de protocole alternatif
EP3779210A4 (fr) Engin de chantier
EP3660330A4 (fr) Engin de chantier
EP3828346A4 (fr) Machine de construction
EP3859167A4 (fr) Engin de chantier
EP3859091A4 (fr) Engin de chantier
EP3779058A4 (fr) Engin de chantier
EP3739131A4 (fr) Machine de construction
EP3767042A4 (fr) Engin de chantier
EP3666580A4 (fr) Engin de chantier électrique
EP3742000A4 (fr) Machine de construction
EP3839267A4 (fr) Machine de construction
EP3892780A4 (fr) Engin de chantier
EP3872354A4 (fr) Engin de chantier
EP3832029A4 (fr) Engin de chantier
EP3795844A4 (fr) Engin de construction
EP3813220A4 (fr) Engin de chantier
EP3744907A4 (fr) Machine de construction
EP3802565A4 (fr) Polypeptides
EP3835490A4 (fr) Engin de chantier

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C12Q0001680000

Ipc: C07K0016220000

A4 Supplementary search report drawn up and despatched

Effective date: 20220422

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20220414BHEP

Ipc: A61K 39/00 20060101ALI20220414BHEP

Ipc: C07K 16/22 20060101AFI20220414BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS